Diversified Consumer Services
Company Overview of The University of Texas M. D. Anderson Cancer Center
The University of Texas M. D. Anderson Cancer Center is an educational institution that offers undergraduate and research programs to physicians, biomedical scientists, and other health-care professionals. The departments include behavioral medicine, biochemistry and molecular biology, cancer biology program, cancer genomics core laboratory, molecular and cellular oncology, molecular genetics, molecular hematology and therapy, molecular therapeutics, and molecular pathology. The University of Texas M. D. Anderson Cancer Center was founded in 1941 as Texas State Cancer Hospital and the Division of Cancer Research and changed its name to M. D. Anderson Hospital for Cancer Research of The Unive...
1515 Holcombe Boulevard
Houston, TX 77030
Founded in 1989
Key Executives for The University of Texas M. D. Anderson Cancer Center
Executive Vice President and Physician-In-Chief
Chairman of Department of Health Disparities Research
Vice President and Head of the Division of Pharmacy
Compensation as of Fiscal Year 2015.
The University of Texas M. D. Anderson Cancer Center Key Developments
Immatics and MD Anderson Announce Launch of Immatics US, Inc., to Develop Multiple T-Cell and TCR-Based Adoptive Cellular Therapies
Aug 26 15
Immatics Biotechnologies GmbH (Immatics) and The University of Texas MD Anderson Cancer Center announced the launch of Immatics US Inc., a new company aiming at becoming a global leader in adoptive cellular therapies (ACT) for the treatment of a range of tumor types. Immatics believes that ACT approaches to be developed by the new company can achieve a step change in the treatment of cancer, by delivering significant, long-lasting clinical benefits. The new company will strive to develop three different ACT approaches for the treatment of tumors with high un-met medical needs, the first of which will enter the clinic in 2016. Immatics US Inc. will develop both autologous and allogenic ACT approaches by capitalizing on MD Anderson's clinical oncology and cell therapy expertise and Immatics' unrivaled cancer target and T-cell receptor (TCR) discovery capabilities. Immatics US Inc. will be based in Houston and has secured a first funding round totaling over $60 million with more than $40 million committed by the parent company Immatics Biotechnologies GmbH and $19.7 million by a recently awarded grant from the Cancer Prevention and Research Institute of Texas (CPRIT). Immatics has been able to use its unique and technology platform XPRESIDENT® for the discovery and further qualification of dozens of novel, proprietary and highly specific cancer targets that can be used as the basis for a range of cancer immunotherapy applications including ACT. This capability will enable Immatics US Inc. to develop TCR-based approaches and to have complementary utility with other approaches for addressing tumor targets. Immatics believes its ACT will be both efficacious and safe due to the specificity of its novel well-characterized targets, including novel over-expressed, cancer-testis and neo-antigens ideally suited for specific and safe ACT approaches.
The University of Texas M.D. Anderson Cancer Center and the University of Texas Medical Branch at Galveston Partner to Expand in League City
Aug 21 15
The University of Texas M.D. Anderson Cancer Center and the University of Texas Medical Branch at Galveston signed a first-ever clinical collaboration agreement that will expand UTMB's League City campus. M.D. Anderson will lease land from UTMB to build a 135,000-square-foot outpatient cancer center on the League City campus. The new center is expected to open by 2018 and will become part of M.D. Anderson's Houston-area network, which includes four clinical care centers. The new outpatient center will complement UTMB's inpatient facility that's under construction on the campus and will be less than eight miles from M.D. Anderson's Bay Area location, which offers medical, radiation and surgical oncology; infusion therapy; pain management; nutrition; and other support services. The new facility will offer patients expanded access to both institutions' health care services. This is the first time local UT System sister institutions have collaborated in such a manner to provide clinical care. The UT System's board of regents approved the collaboration agreement on Aug. 20.
ZIOPHARM Oncology, Inc., Intrexon Corporation and The University of Texas M. D. Anderson Cancer Center Enter into Research and Development Agreement
Aug 21 15
On August 17, 2015, ZIOPHARM Oncology, Inc., Intrexon Corporation and The University of Texas M. D. Anderson Cancer Center entered into a research and development agreement to formalize the scope and process for the transfer by MD Anderson, pursuant to the terms of the License, of certain existing research programs and related technology rights, as well as the terms and conditions for future collaborative research and development of new and ongoing research programs. Pursuant to the Research and Development Agreement, the company, Intrexon and MD Anderson have agreed to form a joint steering committee that will oversee and manage the new and ongoing research programs. As provided under the License, the company will provide funding for research and development activities of MD Anderson in support of certain research programs under the Research and Development Agreement for a period of three years and in an amount of no less than $15 million and no greater than $20 million annually.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|